Literature DB >> 9186828

Autoimmune hepatitis type 2 and hepatitis C virus infection: study of HLA antigens.

A Jurado1, B Cárdaba, P Jara, P Cuadrado, L Hierro, B de Andrés, V del Pozo, M I Cortegano, S Gallardo, C Camarena, R Bárcena, J L Castañer, R Alvarez, C Lahoz, P Palomino.   

Abstract

BACKGROUND/AIMS: Markers for hepatitis C virus are often detectable in patients suffering chronic hepatitis with liver-kidney microsomal type 1 antibodies. Several authors have suggested that two subsets of those patients can be defined: a) hepatitis C virus negative and b) hepatitis C virus positive. The aim of this work was to further analyze the possible genetic association, HLA class I and II, in these two groups of patients.
METHODS: HLA was analyzed in 49 patients. Class I was studied using a standard lymphocytotoxicity test and in class II a reverse hybridization-based test for DRB1 typing and PCR-SSO for DQB1 typing were used. Sixty healthy Spanish subjects and 39 chronic hepatitis C subjects without anti-LKM1 antibodies were used as control groups for the "a" and "b" subsets, respectively.
RESULTS: No significant association was found with class I specificities in either group. DQB1 typing showed a very significant increase of DQ2 in the "a" group (93.3% vs. 48%; RR = 15; Pc = 0.0025), and DRB1 typing from the "b" group revealed a high association with DR7 (82.3% vs. 43.6%; RR = 6; Pc = 0.0086).
CONCLUSIONS: Our studies revealed a strong association with DQ2 for the "a" group and for the first time an extremely high association with DR7 antigen for the "b" subset. Hence it is possible to establish a different genetic profile in these two patient groups.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9186828     DOI: 10.1016/s0168-8278(97)80106-7

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

1.  Relationship between autoimmune hepatitis and HLA-DR4 and DRbeta allelic sequences in the third hypervariable region in Chinese.

Authors:  X Ma; D K Qiu
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

Review 2.  Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

3.  Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes.

Authors:  R Klein; U M Zanger; T Berg; U Hopf; P A Berg
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

4.  Genetic distinctions between autoimmune hepatitis in Italy and North America.

Authors:  Paolo Muratori; Albert-J Czaja; Luigi Muratori; Georgios Pappas; Silvana Maccariello; Fabio Cassani; Alessandro Granito; Rodolfo Ferrari; Vilma Mantovani; Marco Lenzi; Francesco-B Bianchi
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

Review 5.  Influence of genes, sex, age and environment on the onset of autoimmune hepatitis.

Authors:  Kathie Béland; Pascal Lapierre; Fernando Alvarez
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

6.  Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C.

Authors:  Paolo Muratori; Albert J Czaja; Luigi Muratori; Alessandro Granito; Marcello Guidi; Silvia Ferri; Umberto Volta; Wilma Mantovani; Georgios Pappas; Fabio Cassani; Marco Lenzi; Francesco B Bianchi
Journal:  Dig Dis Sci       Date:  2006-12-08       Impact factor: 3.487

7.  Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease.

Authors:  Kalliopi Zachou; Eirini Rigopoulou; George N Dalekos
Journal:  J Autoimmune Dis       Date:  2004-10-15

Review 8.  Type 2 autoimmune hepatitis: Genetic susceptibility.

Authors:  Pascal Lapierre; Fernando Alvarez
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.